Two beliefs about the prostate cause more harm than almost anything else in men’s health, and they’re opposites of each other.
The first is that urinary symptoms mean cancer. They usually don’t. The overwhelming majority of men with a weak stream, night-time waking and urgency have benign enlargement — a normal consequence of ageing that affects most men who live long enough.
The second is that the absence of symptoms means safety. Early prostate cancer is typically asymptomatic. It grows in the peripheral zone of the gland, away from the urethra, so it doesn’t obstruct flow until it’s advanced. By the time cancer causes urinary symptoms, it is usually not early.
So symptoms are a poor guide in both directions. That’s the central problem this article is about, and it’s why the screening question is as contested as it is.
What the prostate is and why it grows
The prostate is a walnut-sized gland sitting below the bladder, wrapped around the urethra. Its function is to produce roughly a third of seminal fluid, including enzymes that liquefy semen after ejaculation and prostate-specific antigen — the protein that later became the screening test.
Its anatomical position is the entire problem. The urethra runs through it. When the gland enlarges, it squeezes the tube it surrounds.
Benign prostatic hyperplasia is that enlargement. It’s driven by dihydrotestosterone, the more potent androgen converted from testosterone by the enzyme 5-alpha reductase within prostate tissue. Growth begins in the transition zone, the part closest to the urethra — which is why a relatively modest amount of enlargement can cause substantial obstruction.
It is close to universal with age. Histological evidence of BPH is present in roughly half of men by 60 and over 80% by age 80. Not all of those men have symptoms — gland size correlates poorly with symptom severity, and a small gland positioned badly can obstruct more than a large one positioned well.
The symptoms, and what they mean
The clinical term is lower urinary tract symptoms — LUTS — and they split into two groups that point in slightly different directions.
Voiding (obstructive) symptoms — the gland is blocking outflow:
- Weak or slow stream
- Hesitancy before flow starts
- Straining
- Intermittent stream, starting and stopping
- Terminal dribbling
- Sensation of incomplete emptying
Storage (irritative) symptoms — the bladder is reacting to years of pushing against resistance, becoming thickened and overactive:
- Urinary frequency
- Urgency
- Nocturia — waking at night to urinate
- Urge incontinence
Storage symptoms are typically what men find most disruptive, and nocturia in particular has a substantial effect on sleep quality and daytime function. It’s also frequently the symptom that finally prompts a consultation, often years after the voiding symptoms began.
The International Prostate Symptom Score (IPSS) is a validated seven-item questionnaire scoring severity from 0 to 35 — mild under 8, moderate 8 to 19, severe 20 and above. It’s freely available, takes two minutes, and completing it before an appointment gives your doctor a far better starting point than a vague description.
Things that are not BPH but look like it
- Urinary tract infection — burning, cloudy or offensive urine, fever
- Diabetes — polyuria from osmotic diuresis; new frequency and thirst warrants a glucose check
- Overactive bladder without obstruction — storage symptoms with a normal flow
- Diuretics taken in the evening, causing nocturia
- Heart failure — fluid mobilised from the legs on lying down causes nocturia; a genuinely important one to catch
- Obstructive sleep apnoea — a recognised and frequently missed cause of nocturia
- Urethral stricture — usually a history of instrumentation, infection or trauma
- Neurological disease — Parkinson’s, MS, spinal pathology
Red flags requiring prompt assessment
- Visible blood in urine or semen
- Complete inability to pass urine with a painful distended bladder — acute retention is an emergency needing catheterisation
- Bone pain, particularly spine, pelvis or hips
- Unexplained weight loss
- New erectile dysfunction alongside urinary symptoms in an older man
- Symptoms with fever and rigors — possible acute prostatitis or pyelonephritis
- Leg weakness or numbness, or saddle anaesthesia — possible cord compression, an emergency
PSA: an honest account of a contested test
This is where reasonable, well-informed clinicians genuinely disagree, and it deserves both sides rather than a recommendation.
PSA is produced by prostate tissue, benign and malignant alike. It rises with cancer — but also with benign enlargement, prostatitis, urinary infection, recent ejaculation, vigorous cycling, catheterisation and digital rectal examination. It is organ-specific, not cancer-specific, and that is the root of every difficulty with it.
The case for screening
The European Randomised Study of Screening for Prostate Cancer (ERSPC), the largest trial, found PSA screening reduced prostate cancer mortality by roughly 20% at extended follow-up. Prostate cancer remains one of the leading causes of male cancer death. Detected early, it is frequently curable; detected late, it is not. Modern pathways — using MRI before biopsy and active surveillance rather than immediate treatment for low-risk disease — have substantially reduced the harms that made earlier screening programmes so problematic.
The case against
The American PLCO trial found no mortality benefit, though it was heavily compromised by contamination — a large share of the control arm was screened anyway.
The deeper problem is overdiagnosis. Autopsy studies consistently find prostate cancer in a large proportion of men who died of unrelated causes — rising with age to a substantial majority of men in their eighties. Much prostate cancer is indolent and will never cause symptoms or death. Screening finds these cancers, and finding them creates a strong pull toward treating them.
The harms of that treatment are not trivial: radical prostatectomy and radiotherapy carry meaningful rates of long-term erectile dysfunction and urinary incontinence. A man rendered impotent and incontinent for a cancer that would never have troubled him has been harmed by screening, and the number needed to treat to prevent one death is high.
False positives also lead to biopsies, which carry bleeding and sepsis risk.
Where the guidelines have landed
Most major bodies now recommend shared decision-making rather than routine universal screening or blanket discouragement — a conversation about individual risk and personal values, typically from age 50, or 45 for men at higher risk: Black men, who have both higher incidence and worse outcomes, and men with a first-degree relative diagnosed young or with BRCA mutations in the family.
The practical position: this is a decision you should make deliberately, with information, rather than have made for you by default in either direction.
Modern practice reduces the old harms
Two developments matter:
MRI before biopsy. The PRECISION trial and others established that multiparametric MRI before biopsy detects more clinically significant cancer while avoiding biopsy altogether in a substantial share of men, and finding fewer insignificant cancers. This directly addresses the overdiagnosis problem.
Active surveillance. Low-risk disease is now monitored rather than treated in most guidelines, with treatment reserved for evidence of progression. Uptake has grown dramatically and has changed the risk-benefit calculation of screening considerably.
Treating BPH
Watchful waiting
For mild symptoms with no complications, this is a legitimate and often correct choice. Many men remain stable for years. Behavioural measures help meaningfully:
- Reduce fluids in the two to three hours before bed
- Cut caffeine and alcohol, both diuretic and bladder-irritant
- Double voiding — urinate, wait, try again
- Timed voiding rather than waiting for urgency
- Review evening diuretics with a prescriber
- Treat constipation, which worsens outflow mechanically
- Pelvic floor exercises for post-void dribbling
Alpha-blockers
Tamsulosin, alfuzosin, doxazosin, silodosin. These relax smooth muscle in the prostate and bladder neck. They do not shrink the gland — they reduce the tone of what’s already there.
Work within days, which makes them the usual first drug. Side effects include dizziness and postural hypotension, particularly with the first dose, and retrograde ejaculation — semen passing backward into the bladder — which is common with tamsulosin and silodosin, harmless, but distressing if unexpected.
Two interactions worth flagging:
Alpha-blockers with PDE5 inhibitors (sildenafil, tadalafil) can cause significant hypotension. The combination is used, but requires stable dosing on one before adding the other, with separation in timing.
Tamsulosin and cataract surgery. Alpha-blockers cause intraoperative floppy iris syndrome, which substantially complicates cataract surgery and raises the risk of complications if the surgeon doesn’t know in advance. The effect can persist long after stopping the drug. Tell any ophthalmic surgeon that you take or have ever taken tamsulosin. This is under-communicated and genuinely matters.
5-alpha reductase inhibitors
Finasteride and dutasteride block conversion of testosterone to DHT, and genuinely shrink the prostate — by around 20 to 25% over six to twelve months. Dutasteride inhibits both enzyme isoforms rather than one, and is stocked here as Dutas and Duprost, with the full range in the dutasteride category.
Key points:
They are slow. Meaningful benefit takes three to six months. Men who expect alpha-blocker speed abandon them early.
They work best in larger glands — generally above 30 to 40ml. In a small prostate the benefit is limited.
They reduce the risk of acute retention and the need for surgery over the long term, which alpha-blockers don’t. This is their main advantage.
They halve PSA. This is critical and frequently missed. After six months on a 5-ARI, your PSA reading must be doubled to be interpreted correctly. A result of 2.0 on dutasteride corresponds to roughly 4.0 untreated. Any doctor interpreting your PSA must know you’re taking one, or a significant rise can be masked.
Sexual side effects are real — reduced libido, erectile dysfunction, ejaculatory volume reduction — occurring in a minority. In most men these resolve on stopping. There is ongoing and genuinely unresolved debate about whether a subset experiences persistent symptoms after discontinuation (“post-finasteride syndrome”); regulators in several countries have added warnings while the evidence remains contested.
Gynaecomastia and breast tenderness occur uncommonly. Any new breast lump needs assessment.
Contraindicated in pregnancy — the tablets shouldn’t be handled by women who are or may become pregnant, due to teratogenic risk to a male foetus.
Blood donation is deferred for a period after stopping, for the same reason.
Combination therapy
An alpha-blocker plus a 5-ARI outperforms either alone for men with larger glands and moderate-to-severe symptoms — established by the MTOPS and CombAT trials. Fast relief from one, long-term gland reduction from the other.
Anticholinergics and beta-3 agonists
Where storage symptoms dominate and obstruction is not severe, drugs targeting the bladder rather than the prostate can be added — solifenacin, or the beta-3 agonist mirabegron, stocked as Mirago 50mg. These need care in significant obstruction, since reducing bladder contraction can precipitate retention.
Tadalafil
Licensed in several countries for BPH symptoms at 5mg daily, and useful where LUTS and erectile dysfunction coexist — which is frequently. Same absolute nitrate contraindication as any PDE5 inhibitor.
Surgical and minimally invasive options
When medication fails or complications develop: TURP remains the reference standard; HoLEP and other enucleation techniques suit larger glands; and minimally invasive options — Urolift, Rezum water vapour therapy, prostatic artery embolisation — offer lower rates of sexual side effects with somewhat less durability.
Prostatitis
Distinct from BPH and frequently confused with it. Four categories:
Acute bacterial prostatitis — fever, rigors, severe pain, urinary symptoms. Unwell, needs urgent antibiotics, occasionally hospital.
Chronic bacterial prostatitis — recurrent infections with the same organism, needing prolonged antibiotic courses.
Chronic prostatitis / chronic pelvic pain syndrome — by far the commonest, accounting for the great majority of cases. Pelvic, perineal or genital pain for three months or more, often with urinary and sexual symptoms, and usually no identifiable infection. Frustrating to treat, frequently mismanaged with repeated futile antibiotic courses. Best evidence supports a multimodal approach — pelvic floor physiotherapy, addressing the neuropathic pain component, and attention to the anxiety and catastrophising that reliably accompany chronic pelvic pain.
Asymptomatic inflammatory prostatitis — found incidentally, needs no treatment.
Prevention: an honest assessment
The evidence here is weaker than the supplement market implies.
Reasonably supported: regular physical activity is associated with lower BPH symptom severity and lower prostate cancer risk. Maintaining a healthy weight — metabolic syndrome is associated with both larger prostates and worse outcomes. Not smoking, which relates to aggressive disease. Managing diabetes.
Plausible but not established: dietary patterns high in vegetables and lower in processed red meat. Lycopene from cooked tomatoes has observational support and no trial confirmation.
Not supported: saw palmetto, despite its dominance of the supplement aisle, failed to outperform placebo in the well-conducted STEP and CAMUS randomised trials, including at escalated doses. Beta-sitosterol and pygeum have weak evidence. Selenium and vitamin E were tested in the large SELECT trial, which was stopped early — vitamin E was associated with a statistically significant increase in prostate cancer incidence. That’s a useful reminder that supplements are not free of downside.
Common questions
Does BPH turn into cancer? No. They’re separate processes in different zones of the gland. Having one doesn’t cause the other, though both become more common with age so they frequently coexist.
Does the digital rectal exam still matter? Its value as a standalone screening tool is limited and several guidelines have de-emphasised it, but it remains useful in assessment — it detects some cancers missed by PSA and gives information about gland size.
Will treatment affect my sex life? Possibly, and it depends on which. Alpha-blockers commonly cause retrograde ejaculation. 5-ARIs can reduce libido and erectile function in a minority. Surgery frequently causes retrograde ejaculation. This is worth discussing explicitly rather than discovering afterwards.
How often should I have PSA tested? There’s no universal answer — it depends on the screening decision you’ve made, your baseline, age and risk. If you’re on a 5-ARI, remember the doubling rule.
Is nocturia always the prostate? No. Evening fluids, diuretics, heart failure, diabetes and sleep apnoea all cause it. Isolated nocturia with a normal stream points away from obstruction.
Should I be worried about ejaculation frequency? Several large cohort studies have found higher ejaculation frequency associated with modestly lower prostate cancer risk. Observational, so causation isn’t established — but there’s certainly no evidence of harm.
The short version
Urinary symptoms after 45 are usually benign enlargement, not cancer. But early cancer causes no symptoms, so symptoms are a poor guide either way — which is precisely why the screening decision has to be made deliberately rather than by default.
Complete an IPSS before your appointment. Rule out the mimics — infection, diabetes, medication timing, heart failure, sleep apnoea. Start with behavioural measures. Alpha-blockers work fast but don’t change the gland; 5-ARIs are slow but shrink it and reduce the chance of needing surgery, and they halve your PSA, which everyone interpreting it must know.
Tell any eye surgeon if you’ve ever taken tamsulosin. Skip the saw palmetto. And have the PSA conversation properly, with the harms and benefits laid out, rather than either sleepwalking into it or avoiding it.
More in our men’s health articles and the men’s health range. Questions — get in touch.
This article is general health information and not individual medical advice. Dutasteride, finasteride, alpha-blockers and mirabegron are prescription-only medicines requiring assessment and monitoring. Urinary symptoms in men over 45 warrant proper evaluation — including exclusion of infection, diabetes and other causes — and the decision about PSA testing should be made with a doctor who knows your individual risk factors.
